Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

AEMPS autoriza su ensayo con secretomas dirigidos para tratar la tormenta de citoquinas

by Peaches Biotech

2 years ago
PRS® CK STORM, citoquinas, secretomas

EL PRS® CK-Storm será el primero de una serie de medicamentos, basados en el uso de secretomas dirigidos, para ayudarán a combatir diferentes tipos de patologías autoinmunes.

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

by Ysios Capital

2 years ago
metastatic and/or unresectable STS, Soft Tissue Sarcoma (STS), ADCE-D01

The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS

UB researchers design a drug capable of acting simultaneously against three different therapeutic targets

by Universitat de Barcelona

2 years ago
oligonucleotide drugs (ASOs), RNase H enzyme

It has been developed a new pharmacological tool capable of simultaneously administering three oligonucleotide-based drugs, each acting against a different therapeutic target within the cell

ORYZON announces formal grant of key European patent for vafidemstat

by Oryzon Genomics

2 years ago
borderline personality disorder (BPD), schizophrenia, Vafidemstat, EP3661510B1

Oryzon announced today that the European Patent Office (EPO) has now formally granted Oryzon’s European patent EP3661510B1, titled “Methods of treating behavior alterations” related to vafidemst...

New magnetic nanodrugs enable precise targeting of colon cancer cells, improving treatment options for patients

by Instituto de Investigación Biosanitaria - Ibs Granada

2 years ago
Colon cancer, Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)

Researchers from the ibs.GRANADA and the UGR have developed a new nanodrug using magnetic particles specifically designed to combat colon cancer

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

by Asebio

2 years ago
ATX-01, Myotonic Dystrophy Type 1 (DM1), muscle blind like (MBNL) proteins, DMPK, ARTHEx

ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1

Organ-on-Chips to reduce animal testing

by IBEC - Institut de Bioenginyeria de Catalunya

2 years ago
UNLOOC

The consortium aims to develop Organ-on-Chips technologies to reduce the use of animals in drug development and testing, and to improve the accuracy and personalisation of medical treatments.

Inteligencia artificial para desarrollar fármacos en tiempo récord

by Universidad Politécnica de Madrid

2 years ago
algoritmo “XG4REPO” (eXplainable Graphs for Repurposing), reposicionamiento

Este nuevo algoritmo −llamado “XG4REPO” (eXplainable Graphs for Repurposing)− no sólo reposiciona, sino que además presenta los resultados de forma que sean comprensibles, indicando qué mec...

First patient in the world treated with a new therapeutic strategy to target cancer stem cells

by VHIO

2 years ago
AOP208, serotonin 1B receptor

The drug AOP208 blocks a particular conformation of the serotonin 1b receptor on the membrane of cancer stem cells, which controls metabolic pathways whose blockade may be crucial for the initiation a...

PharmaMar anuncia resultados positivos y estadísticamente significativos de supervivencia global y supervivencia libre de progresión de Zepzelca® (lurbinectedina)

by Asebio

2 years ago
Zepzelca®, Jazz Pharmaceuticals, cáncer de pulmón de célula pequeña (CPCP)

PharmaMar y su socio Jazz Pharmaceuticals plc han anunciado hoy resultados preliminares positivos del ensayo en fase III que evalúa Zepzelca® (lurbinectedin) en combinación con el inhibidor de PD-L...

Biointaxis capta 2,17 millones en fondos públicos para el desarrollo de una terapia génica para la ataxia de Friedreich

by Biointaxis

2 years ago
Biointaxis, FRATAXAV, ataxia de Friedreich

Desde su constitución en 2018 como una spin-off biotecnológica, Biointaxis ha centrado sus esfuerzos en el desarrollo de FRATAXAV®, un fármaco de terapia génica que permite acceder al sistema ner...

Aura Biosciences has reported Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early - Stage Choroidal Melanoma

by Ysios Capital

2 years ago
bel-sar (AU-011), NMIBC, Aura Biosciences

Bel-sar is a virus-like drug conjugate, designed to have a dual mechanism of action, that induces direct tumor cell necrosis and elicits a robust and durable anti-tumor immune response.